Frazer Supply CAS 36322-90-4 Best Piroxicam Price Piroxicam Powder

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Light Yellow Powder
• Purity: >99%
• Model NO.: Frazer-Piroxicam
• Appearance: Light Yellow Powder
• CAS No: 36322-90-4
• Shelf Life: 2 Years
• Test Method: HPLC
• Storage: Store Cool Dry Place
• Quality Requirement: Strictly Quality Control
• Grade: Phamaceutical Grade
• Mf: C15h13n3o4s
• M.W.: 331.346
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 2000kg/Month

Product Description

99% Pharmaceutical Grade Piroxicam CAS 36322-90-4 with High Quality

Specification of Analysis

ITEM	SPECIFICATIONS		Test Results
Characteristics	White or light yellow powder		Complies
Solubility	Practically insoluble in water		Complies
Identification	Positive		Complies
Residue on ignition	≤0.3%		0.05%
Heavy metals	≤0.002%		0.0003%
Water	≤0.5%		0.11%
Organic volatile impurities
Mettylene chlorid	<500PPM		<500PPM
	<50PPM		<50PPM
	<80PPM		<80PPM
1,4-_Dioxane	<100PPM		<100PPM
Benzene	<2PPM		<2PPM
Assay(on dried basis)	97.0-103.0%		99.74%
Conclusion	THE PRODUCT CONFORMS TO USP32

Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class used to relieve the symptoms of painful, inflammatory conditions like arthritis. Piroxicam works by preventing the production of endogenous prostaglandins which are involved in the mediation of pain, stiffness, tenderness and swelling.

Prodcut Function

Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class used to relieve the symptoms of painful, inflammatory conditions like arthritis. Piroxicam works by preventing the production of a certain type of body chemical called prostaglandins which are involved in the mediation of pain, stiffness, tenderness and swelling. The medicine is available as capsules, tablets and (not in all countries) as a prescription-free gel 0.5%. It is also available in a betadex formulation, which allows a more rapid absorption of piroxicam from the digestive tract.

It was originally brought to market by Pfizer under the tradename Feldene in 1980, became generic in 1992, and is marketed worldwide under many brandnames.

It used in the treatment of rheumatoid and osteoarthritis, primary dysmenorrhoea, postoperative pain; and act as an analgesic, especially where there is an inflammatory component. The European Medicines Agency issued a review of its use in 2007 and recommended that its use be limited to the treatment of chronic inflammatory conditions, as it only in these circumstances that its risk-benefit ratio proves to be favourable.